Browse > Article
http://dx.doi.org/10.5808/GI.2016.14.3.112

In Silico Study of miRNA Based Gene Regulation, Involved in Solid Cancer, by the Assistance of Argonaute Protein  

Rath, Surya Narayan (BIF Centre, Department of Bioinformatics, Orissa University of Agriculture & Technology)
Das, Debasrita (BIF Centre, Department of Bioinformatics, Orissa University of Agriculture & Technology)
Konkimalla, V Badireenath (School of Biological Sciences, National Institute of Science Education and Research)
Pradhan, Sukanta Kumar (BIF Centre, Department of Bioinformatics, Orissa University of Agriculture & Technology)
Publication Information
Genomics & Informatics / v.14, no.3, 2016 , pp. 112-124 More about this Journal
Abstract
Solid tumor is generally observed in tissues of epithelial or endothelial cells of lung, breast, prostate, pancreases, colorectal, stomach, and bladder, where several genes transcription is regulated by the microRNAs (miRNAs). Argonaute (AGO) protein is a family of protein which assists in miRNAs to bind with mRNAs of the target genes. Hence, study of the binding mechanism between AGO protein and miRNAs, and also with miRNAs-mRNAs duplex is crucial for understanding the RNA silencing mechanism. In the current work, 64 genes and 23 miRNAs have been selected from literatures, whose deregulation is well established in seven types of solid cancer like lung, breast, prostate, pancreases, colorectal, stomach, and bladder cancer. In silico study reveals, miRNAs namely, miR-106a, miR-21, and miR-29b-2 have a strong binding affinity towards PTEN, TGFBR2, and VEGFA genes, respectively, suggested as important factors in RNA silencing mechanism. Furthermore, interaction between AGO protein (PDB ID-3F73, chain A) with selected miRNAs and with miRNAs-mRNAs duplex were studied computationally to understand their binding at molecular level. The residual interaction and hydrogen bonding are inspected in Discovery Studio 3.5 suites. The current investigation throws light on understanding miRNAs based gene silencing mechanism in solid cancer.
Keywords
Argonaute; in silico; microRNAs; mRNA; solid cancer;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Lin SL, Chiang A, Chang D, Ying SY. Loss of miR-146a function in hormone-refractory prostate cancer. RNA 2008;14:417-424.   DOI
2 Labbaye C, Testa U. The emerging role of miR-146A in the control of hematopoiesis, immune function and cancer. J Hematol Oncol 2012;5:13.   DOI
3 Zhang CM, Zhao J, Deng HY. MiR-155 promotes proliferation of human breast cancer MCF-7 cells through targeting tumor protein 53-induced nuclear protein 1. J Biomed Sci 2013;20:79.   DOI
4 Liu J, Huang W, Yang H, Luo Y. Expression and function of miR-155 in breast cancer. Biotechnol Biotechnol Equip 2015;29:840-843.   DOI
5 Mansueto G, Forzati F, Ferraro A, Pallante P, Bianco M, Esposito F, et al. Identification of a new pathway for tumor progression: microRNA-181b up-regulation and CBX7 down-regulation by HMGA1 protein. Genes Cancer 2010;1:210-224.   DOI
6 Li Y, Vandenboom TG 2nd, Wang Z, Kong D, Ali S, Philip PA, et al. miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res 2010;70:1486-1495.   DOI
7 Hutvagner G, Simard MJ. Argonaute proteins: key players in RNA silencing. Nat Rev Mol Cell Biol 2008;9:22-32.   DOI
8 Sun Q, Zhao X, Liu X, Wang Y, Huang J, Jiang B, et al. miR-146a functions as a tumor suppressor in prostate cancer by targeting Rac1. Prostate 2014;74:1613-1621.   DOI
9 Li BS, Zuo QF, Zhao YL, Xiao B, Zhuang Y, Mao XH, et al. MicroRNA-25 promotes gastric cancer migration, invasion and proliferation by directly targeting transducer of ERBB2, 1 and correlates with poor survival. Oncogene 2015;34:2556-2565.   DOI
10 Hamano R, Ishii H, Miyata H, Doki Y, Mori M. Role of microRNAs in solid tumors. J Nucleic Acids Investig 2011;2:e2.   DOI
11 Aslam MI, Patel M, Singh B, Jameson JS, Pringle JH. MicroRNA manipulation in colorectal cancer cells: from laboratory to clinical application. J Transl Med 2012;10:128.   DOI
12 Das RP, Konkimalla VB, Rath SN, Hansa J, Jagdeb M. Elucidation of the molecular interaction between miRNAs and the HOXA9 gene, involved in acute myeloid leukemia, by the assistance of Argonaute protein through a computational approach. Genomics Inform 2015;13:45-52.   DOI
13 Mascellani N, Tagliavini L, Gamberoni G, Rossi S, Marchesini J, Taccioli C, et al. Using miRNA expression data for the study of human cancer. Minerva Biotecnol 2008;20:23-30.
14 Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol Cell 2010;39:493-506.   DOI
15 Zhu N, Zhang D, Xie H, Zhou Z, Chen H, Hu T, et al. Endothelial-specific intron-derived miR-126 is down-regulated in human breast cancer and targets both VEGFA and PIK3R2. Mol Cell Biochem 2011;351:157-164.   DOI
16 Chi SW, Zang JB, Mele A, Darnell RB. Argonaute HITS-CLIP decodes microRNA-mRNA interaction maps. Nature 2009;460:479-486.   DOI
17 Baffa R, Fassan M, Volinia S, O'Hara B, Liu CG, Palazzo JP, et al. MicroRNA expression profiling of human metastatic cancers identifies cancer gene targets. J Pathol 2009;219:214-221.   DOI
18 Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, Benz CC. Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 2008;27:5643-5647.   DOI
19 Liu K, Li G, Fan C, Diao Y, Wu B, Li J. Increased expression of microRNA-221 in gastric cancer and its clinical significance. J Int Med Res 2012;40:467-474.   DOI
20 Li X, Zhang Y, Zhang H, Liu X, Gong T, Li M, et al. miRNA-223 promotes gastric cancer invasion and metastasis by targeting tumor suppressor EPB41L3. Mol Cancer Res 2011;9:824-833.   DOI
21 Li ZW, Yang YM, Du LT, Dong Z, Wang LL, Zhang X, et al. Overexpression of miR-223 correlates with tumor metastasis and poor prognosis in patients with colorectal cancer. Med Oncol 2014;31:256.   DOI
22 Yabushita S, Fukamachi K, Tanaka H, Sumida K, Deguchi Y, Sukata T, et al. Circulating microRNAs in serum of human K-ras oncogene transgenic rats with pancreatic ductal adenocarcinomas. Pancreas 2012;41:1013-1018.   DOI
23 Junn E, Mouradian MM. MicroRNAs in neurodegenerative diseases and their therapeutic potential. Pharmacol Ther 2012;133:142-150.   DOI
24 Wang Y, Yu Y, Tsuyada A, Ren X, Wu X, Stubblefield K, et al. Transforming growth factor-$\beta$ regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM. Oncogene 2011;30:1470-1480.   DOI
25 Popenda M, Szachniuk M, Antczak M, Purzycka KJ, Lukasiak P, Bartol N, et al. Automated 3D structure composition for large RNAs. Nucleic Acids Res 2012;40:e112.   DOI
26 Schneidman-Duhovny D, Inbar Y, Nussinov R, Wolfson HJ. PatchDock and SymmDock: servers for rigid and symmetric docking. Nucleic Acids Res 2005;33:W363-W367.   DOI
27 Lee KH, Lotterman C, Karikari C, Omura N, Feldmann G, Habbe N, et al. Epigenetic silencing of microRNA miR-107 regulates cyclin-dependent kinase 6 expression in pancreatic cancer. Pancreatology 2009;9:293-301.   DOI
28 Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 2008;68:6162-6170.   DOI
29 Zhang XJ, Ye H, Zeng CW, He B, Zhang H, Chen YQ. Dysregulation of miR-15a and miR-214 in human pancreatic cancer. J Hematol Oncol 2010;3:46.   DOI
30 Wu W, Yang J, Feng X, Wang H, Ye S, Yang P, et al. Micro-RNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells. Mol Cancer 2013;12:30.   DOI
31 Yu J, Ohuchida K, Mizumoto K, Fujita H, Nakata K, Tanaka M. MicroRNA miR-17-5p is overexpressed in pancreatic cancer, associated with a poor prognosis, and involved in cancer cell proliferation and invasion. Cancer Biol Ther 2010;10:748-757.   DOI
32 Azrak SS, Ginel-Picardo A, Drosten M, Barbacid M, Santos E. Reversible, interrelated mRNA and miRNA expression patterns in the transcriptome of Rasless fibroblasts: functional and mechanistic implications. BMC Genomics 2013;14:731.   DOI
33 Feng B, Dong TT, Wang LL, Zhou HM, Zhao HC, Dong F, et al. Colorectal cancer migration and invasion initiated by microRNA-106a. PLoS One 2012;7:e43452.   DOI
34 Li XM, Wang AM, Zhang J, Yi H. Down-regulation of miR-126 expression in colorectal cancer and its clinical significance. Med Oncol 2011;28:1054-1057.   DOI
35 Wu W, Yang P, Feng X, Wang H, Qiu Y, Tian T, et al. The relationship between and clinical significance of microRNA-32 and phosphatase and tensin homologue expression in colorectal cancer. Genes Chromosomes Cancer 2013;52:1133-1140.   DOI
36 Qin S, Zhu Y, Ai F, Li Y, Bai B, Yao W, et al. MicroRNA-191 correlates with poor prognosis of colorectal carcinoma and plays multiple roles by targeting tissue inhibitor of metalloprotease 3. Neoplasma 2014;61:27-34.   DOI
37 Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A 2006;103:2257-2261.   DOI
38 Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007;302:1-12.   DOI
39 Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010;126:1166-1176.
40 Grammatikakis I, Gorospe M, Abdelmohsen K. Modulation of cancer traits by tumor suppressor microRNAs. Int J Mol Sci 2013;14:1822-1842.   DOI
41 Esquela-Kerscher A, Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006;6:259-269.   DOI
42 Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, et al. MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene. Oncogene 2008;27:4373-4379.   DOI
43 Xu LF, Wu ZP, Chen Y, Zhu QS, Hamidi S, Navab R. MicroRNA-21 (miR-21) regulates cellular proliferation, invasion, migration, and apoptosis by targeting PTEN, RECK and Bcl-2 in lung squamous carcinoma, Gejiu City, China. PLoS One 2014;9:e103698.   DOI
44 Wang P, Zou F, Zhang X, Li H, Dulak A, Tomko RJ Jr, et al. microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells. Cancer Res 2009;69:8157-8165.   DOI
45 Gong AY, Eischeid AN, Xiao J, Zhao J, Chen D, Wang ZY, et al. miR-17-5p targets the p300/CBP-associated factor and modulates androgen receptor transcriptional activity in cultured prostate cancer cells. BMC Cancer 2012;12:492.   DOI
46 Alison RM. Encyclopedia of Life Sciences: Cancer. London: Nature Publishing Group, 2001.
47 Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol 2009;4:199-227.   DOI
48 Nagpal N, Kulshreshtha R. miR-191: an emerging player in disease biology. Front Genet 2014;5:99.
49 Fang L, Li H, Wang L, Hu J, Jin T, Wang J, et al. Micro-RNA-17-5p promotes chemotherapeutic drug resistance and tumour metastasis of colorectal cancer by repressing PTEN expression. Oncotarget 2014;5:2974-2987.   DOI
50 Yamada N, Kitamoto S, Yokoyama S, Hamada T, Goto M, Tsutsumida H, et al. Epigenetic regulation of mucin genes in human cancers. Clin Epigenetics 2011;2:85-96.   DOI
51 Wang H, Guan X, Tu Y, Zheng S, Long J, Li S, et al. MicroRNA-29b attenuates non-small cell lung cancer metastasis by targeting matrix metalloproteinase 2 and PTEN. J Exp Clin Cancer Res 2015;34:59.   DOI
52 Liu H, Wang B, Lin J, Zhao L. microRNA-29b: an emerging player in human cancer. Asian Pac J Cancer Prev 2014;15:9059-9064.   DOI
53 Ru P, Steele R, Newhall P, Phillips NJ, Toth K, Ray RB. miRNA-29b suppresses prostate cancer metastasis by regulating epithelial-mesenchymal transition signaling. Mol Cancer Ther 2012;11:1166-1173.   DOI
54 Wang Y, Li Y, Ma Z, Yang W, Ai C. Mechanism of micro-RNA-target interaction: molecular dynamics simulations and thermodynamics analysis. PLoS Comput Biol 2010;6:e1000866.   DOI
55 Gong J, Li J, Wang Y, Liu C, Jia H, Jiang C, et al. Characterization of microRNA-29 family expression and investigation of their mechanistic roles in gastric cancer. Carcinogenesis 2014;35:497-506.   DOI
56 Wu LH, Cai QQ, Dong YW, Wang R, He BM, Qi B, et al. Decoy oligonucleotide rescues IGF1R expression from microRNA-223 suppression. PLoS One 2013;8:e82167.   DOI
57 Zhang Y, Fan KJ, Sun Q, Chen AZ, Shen WL, Zhao ZH, et al. Functional screening for miRNAs targeting Smad4 identified miR-199a as a negative regulator of TGF-$\beta$ signalling pathway. Nucleic Acids Res 2012;40:9286-9297.   DOI
58 Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008;27:5959-5974.   DOI
59 Yin Y, Li J, Chen S, Zhou T, Si J. MicroRNAs as diagnostic biomarkers in gastric cancer. Int J Mol Sci 2012;13:12544-12555.   DOI
60 Ding G, Huang G, Liu HD, Liang HX, Ni YF, Ding ZH, et al. MiR-199a suppresses the hypoxia-induced proliferation of non-small cell lung cancer cells through targeting $HIF1{\alpha}$. Mol Cell Biochem 2013;384:173-180.   DOI
61 Zhu X, Li H, Long L, Hui L, Chen H, Wang X, et al. miR-126 enhances the sensitivity of non-small cell lung cancer cells to anticancer agents by targeting vascular endothelial growth factor A. Acta Biochim Biophys Sin (Shanghai) 2012;44:519-526.   DOI
62 Zhou Y, Feng X, Liu YL, Ye SC, Wang H, Tan WK, et al. Down-regulation of miR-126 is associated with colorectal cancer cells proliferation, migration and invasion by targeting IRS-1 via the AKT and ERK1/2 signaling pathways. PLoS One 2013;8:e81203.   DOI
63 Liao YL, Tsai KW, Lin WC. miRNAs in gastric cancer. Rijeka: INTECH Open Access Publisher, 2011.
64 Zhang Q, Padi SK, Tindall DJ, Guo B. Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31. Cell Death Dis 2014;5:e1486.   DOI
65 Jia AY, Castillo-Martin M, Bonal DM, Sanchez-Carbayo M, Silva JM, Cordon-Cardo C. MicroRNA-126 inhibits invasion in bladder cancer via regulation of ADAM9. Br J Cancer 2014;110:2945-2954.   DOI
66 Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 2010;120:1298-1309.   DOI